Thank you, Mr. Chair.
I'd like to thank the witnesses appearing before us today. This information is very helpful.
Dr. Prémont, your explanation of Quebec's experience over the last 20 years and the reasons why the program is so costly compared to regimes in other OECD countries were very clear. It was also clear that, in the case of a program like Quebec's, some shortcomings might be countered by a universal public program intended for all of Canada.
Dr. Gagnon, you said that there was no economic obstacle to implementing this program. Yet, in the context of this committee's work, the minister said last week that she thought a pharmacare program would be too expensive. So you can understand why cost is a concern for our committee.
I don't know if one of you could tell me how much the Government of Canada is already spending annually on tax credits to companies that offer their employees a drug coverage plan.